¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"insulin tolerance"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • oxygen tolerance
    »ê¼Ò³»¼º
  • self-tolerance
    1. ÀÚ°¡°ü¿ë 2. ÀÚ°¡³»¼º
  • crystalline insulin
    °áÁ¤Àν¶¸°
  • depot insulin
    ÀúÀåÀν¶¸°
  • fast-acting insulin
    ±Þ¼ÓÀÛ¿ëÀν¶¸°
  • immunoreactive insulin
    ¸é¿ª¹ÝÀÀÀν¶¸°
  • insulin
    Àν¶¸°
  • insulin clamp
    Àν¶¸°Å¬·¥ÇÁ
  • insulin receptor
    Àν¶¸°¼ö¿ëü
  • insulin receptor substrate-1
    Àν¶¸°¼ö¿ëü±âÁú-1
  • insulin resistance
    Àν¶¸°ÀúÇ×, Àν¶¸°³»¼º
  • insulin sensitivity index
    Àν¶¸°¹Î°¨Áö¼ö
  • insulin shock
    Àν¶¸°¼îÅ©
  • insulin-dependent
    Àν¶¸°ÀÇÁ¸-
  • insulin-dependent diabetes
    Àν¶¸°ÀÇÁ¸´ç´¢º´
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • insulin-to-glucose ratio
    Àν¶¸°Æ÷µµ´çºñÀ²
  • long acting insulin
    Áö¼ÓÀν¶¸°
  • purified insulin
    ¼ø¼öÀν¶¸°
  • short acting insulin
    ´Ü±âÀÛ¿ëÀν¶¸°
  • suppressive insulin
    ¾ïÁ¦Àν¶¸°
  • acceleration tolerance
    °¡¼Ó³»¼º
  • acquired tolerance
    ȹµæÇã¿ë, ÈÄõ³»¼º, ÈÄõÇã¿ë, ȹµæ°ü¿ë
  • adoptive tolerance
    ÀÔ¾ç¸é¿ªÇã¿ë
  • cross-tolerance
    ±³Â÷³»¼º
  • carbohydrate tolerance test
    ź¼öÈ­¹°³»¼º½ÃÇè
  • cortisone glucose tolerance test
    ÄÚ¸£Æ¼¼ÕÆ÷µµ´çºÎÇϽÃÇè
  • cross tolerance
    ±³Â÷³»¼º
  • drug tolerance
    ¾à¹°³»¼º, ¾à¹°ÀúÇ×¼º
  • maximum tolerance dose
    ÃÖ´ë³»¾à¿ë·®, ÃÖ´ë³»¾à·®, ÃÖ´ë°ßµõ¼±·®
  • organ tolerance dose
    ±â°ü°ßµõ¼±·®
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • insulin sensitivity index
    Àν¶¸°°¨¼ºÁö¼ö.
  • insulin sensitivity test
    Àν¶¸°°¨¼º½ÃÇè.
  • insulin shock
    Àν¶¸°¼ï.
  • insulin shock therapy
    Àν¶¸°¼ï¿ä¹ý.
  • insulin shock treatment
    Àν¶¸°Ãæ°ÝÄ¡·á.
  • insulin test
    Àν¶¸°½ÃÇè.
  • insulin therapy
    Àν¶¸°Ä¡·á, Àν¶¸°¿ä¹ý.
  • protamin insulin(e)
    ÇÁ·ÎŸ¹ÎÀν¶¸°.
  • protamin(e) insulin
    ÇÁ·ÎŸ¹ÎÀν¶¸°.
  • protamin(e) zinc insulin
    ÇÁ·ÎŸ¹Î¾Æ¿¬ Àν¶¸°.
  • protamin(e) zinc insulin
    ÇÁ·ÎŸ¹Î¾Æ¿¬ Àν¶¸°.
  • GTT= glucose tolerance test
    ´çºÎÇÏ °Ë»ç.
  • Glucose tolerance
    ³»´ç·Â(Ò±ÓØÕô)
  • Gudmand-Hoyer lactose tolerance test
    ±¸µÎ¸¸-È£À̾î À¯´çºÎÇϽÃÇè
  • MTD=£¾maximum tolerance dose
    ÃÖ´ë³»¿ë·®.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • insulin antagonist
    Àν¶¸°±æÇ×ü.
  • insulin antagonist
    Àν¶¸°±æÇ×Á¦.
  • insulin antiserum
    Ç×Àν¶¸°Ç÷û.
  • insulin coma therapy
    Àν¶¸° È¥¼ö Ä¡·á
  • insulin convulsive therapy combined
    Àν¶¸°°æ·Ãº´ÇÕÄ¡·á<¿ä¹ý>
  • insulin convulsive therapy combined
    Àν¶¸°°æ·Ãº´ÇÕÄ¡·á<¿ä¹ý>.
  • insulin deficiency diabetes
    Àν¶¸°°áÇ̼º ´ç´¢º´.
  • insulin dependence
    Àν¶¸°ÀÇÁ¸¼º.
  • insulin dependent diabetes mellitus =IDDM
    Àν¶¸°ÀÇÁ¸¼º ´ç´¢º´.
  • insulin edema
    Àν¶¸°ºÎÁ¾(¡­Ý©ðþ).
  • insulin like activity =ILa
    Àν¶¸°¾çȰ¼º(ÀÛ¿ë).
  • insulin lipodystrophy
    Àν¶¸°Áö¹æÀÌ¿µ¾çÁõ.
  • insulin receptor
    Àν¶¸°¼ö¿ëü.
  • insulin receptor
    Àν¶¸°¼ö¿ëü(áôé»ô÷).
  • insulin resistance
    Àν¶¸°ÀúÇ×¼º.
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • bound insulin
    °áÇÕ(Ì¿ùê)Àν¶¸°
  • desalanine insulin
    ¾Ë¶ó´ÑÁ¦°Å(ð¶ËÛ)Àν¶¸°
  • free insulin
    À¯¸®(ë´×î) Àν¶¸°
  • globin zinc insulin
    ±Û·Îºó ¾Æ¿¬(䬿ç)Àν¶¸°
  • immunoreactive insulin
    ¸é¿ª¹ÝÀÀ¼º(Øóæ¹Úãëëàõ) Àν¶¸°
  • insulin
    Àν¶¸°
  • insulin resistance index
    Àν¶¸° ÀúÇ×Áö¼ö(î½ù÷ò¦â¦)
  • insulin shock
    Àν¶¸° ¼ï
  • insulin stimulating test
    Àν¶¸° ÀڱؽÃÇè(í©Ð½ãËúÐ)
  • isophane insulin
    ¾ÆÀÌ¼ÒÆÇ Àν¶¸°
  • lente insulin
    ·»Å×Àν¶¸°
  • NPH insulin
    NPH Àν¶¸°
  • protamine zinc insulin
    ÇÁ·ÎŸ¹Î ¾Æ¿¬(䬿ç) Àν¶¸°
  • suppressible insulin-like activity
    ¾ï¾Ð °¡´É(åääâʦÒö) Àν¶¸°À¯»çȰ¼º(×¾ÞÄüÀàõ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
ITT insulin tolerance test; internal tibial torsion
NPH   1) Neutral Protamine Hagedorn Insulin
    = Isophane Insulin Susp...
IRI immunoreactive insulin; insulin resistance index
IRS immunoreactive secretion; infrared spectrophotometry; insulin receptor species; insulin receptor sub...
IST inappropriate sinus tachycardia; insulin sensitivity test; insulin shock therapy; International Soci...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
75 g Glucose Tolerance Test
GTT Glucose Tolerance Test
GT Glucose tolerance
IVGTT I.v. glucose tolerance tests
ITI Immune tolerance induction
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • carbohydrate tolerance
    ź¼öÈ­¹° ºÎÇÏ, ź¼öÈ­¹° ³»Àμº
  • cortisone glucose tolerance test
    ÄÚ¸£Æ¼¼Õ Æ÷µµ´ç ºÎÇÏ ½ÃÇè
  • cross tolerance
    ±³Â÷ ³»¼º
  • drug disposition tolerance
    ¾à¹° ºÐÇØ ³»¼º
  • EDTA tolerance test
    EDTA ³»¼º °Ë»ç
    Á¤¸Æ Åõ¿©ÇÏ¿© ºÎ°©»ó¼± È£¸£¸óÀÇ ºÐºñ¸¦ ÃËÁø½ÃŰ´Â °ÍÀÌ ¸ñÀûÀÌ´Ù.
  • exercise tolerance test
    ¿îµ¿ ºÎÇÏ °Ë»ç
  • high dose tolerance
    °í¿ª ¿ªÄ¡
  • immunological tolerance
    ¸é¿ª ³»¼º
    ´Ù¸¥ »óÅ¿¡¼­´Â ü¾×¼º ¶Ç´Â ¼¼Æ÷ ¸Å°³ ¸é¿ªÀ» À¯¹ßÇÒ ¼ö Àִ ƯÁ¤ÀÇ Ç׿ø¿¡ ´ëÇØ¼­, ¸²ÇÁ°è Á¶Á÷ÀÇ Æ¯ÀÌÀû ¹«¹ÝÀÀ¼ºÀÌ ÀϾµµ·Ï µÇ´Â °ÍÀ» Ư¡ÀûÀ¸·Î ÇÏ´Â ¸é¿ª ¹ÝÀÀ.
  • individual tolerance
    °³Àκ° ³»¼º
    ºñÁ¤»óÀûÀ¸·Î ´ë·®ÀÇ ¾à¹°¿¡ ´ëÇÏ¿© µ¶¿µÇâÀ» ¹ÞÁö ¾Ê°í °ßµð¸ç ¶ÇÇÑ ÀÏÁ¤·®ÀÇ ¾à¹°ÀÇ Áö¼ÓÀûÀÎ »ç¿ë¿¡ ´ëÇØ¼­ È¿°úÀÇ °¨¼Ò¸¦ ³ªÅ¸³»´Â ´É·Â.
  • lactose tolerance test
    ¶ôÅä¿À½º ³»¼º ½ÃÇè
  • maximum tolerance dose
    ÃÖ´ë ³»¿ë·®, ÃÖ´ë °ßµõ ¼±·®
  • median tolerance limit
    ¹Ý¼ö »ýÁ¸ ÇÑ°è ³óµµ
  • organ tolerance dose
    ±â°ü Çã¿ë·®, Àå±â Çã¿ë·®
  • pain tolerance
    µ¿Åë ³»¼º, ÅëÁõ ³»¼º
    ÂüÀ» ¼ö ÀÖ´Â ÅëÁõÀÇ °¡Àå Å« ¼öÁØ.
  • pharmacodynamic tolerance
    ¾à¿ªÇÐÀû ³»¼º
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
split tolerance Modification of an immune response to an antigen after prior exposure to that antigen.
Synonym: split tolerance.
(05 Mar 2000)
nonresponder tolerance Lack of immune response to antigen. Theories of tolerance induction include clonal deletion and clonal anergy. In clonal deletion, the actual clone of cells is eliminated whereas in clonal anergy the cells are present but nonfunctional.
Synonym: immunological tolerance, immunotolerance, nonresponder tolerance.
(05 Mar 2000)
drug tolerance Progressive diminution of the susceptibility of a human or animal to the effects of a drug, resulting from its continued administration. It should be differentiated from drug resistance wherein a human, animal, disease, or tissue fails to respond to the intended effectiveness of a chemical or drug.
(12 Dec 1998)
immune tolerance The specific failure of a normally responsive individual to make an immune response to a known antigen. It results from previous contact with the antigen by an immunologically immature individual (foetus or neonate) or by an adult exposed to extreme high-dose or low-dose antigen, or by exposure to radiation, antimetabolites, antilymphocytic serum, etc.
(12 Dec 1998)
immunological tolerance <immunology> Specific unresponsiveness to antigen. Self tolerance is a process occurring normally early in life due to suppression of self reactive lymphocyte clones.
Tolerance to foreign antigens can be induced in adult life by exposure to antigens under conditions in which specific clones are suppressed. Note that tolerance is not the same as immunological unresponsiveness, since the latter may be very non-specific as in immunodeficiency states.
(18 Nov 1997)
immunologic high dose tolerance Induction of tolerance by exposure to large amounts of protein antigens.
(05 Mar 2000)
immunologic tolerance Lack of immune response to antigen. Theories of tolerance induction include clonal deletion and clonal anergy. In clonal deletion, the actual clone of cells is eliminated whereas in clonal anergy the cells are present but nonfunctional.
Synonym: immunological tolerance, immunotolerance, nonresponder tolerance.
(05 Mar 2000)
impaired glucose tolerance Blood glucose (sugar) levels higher than normal but not high enough to be called diabetes. People with impaired glucose tolerance may or may not develop diabetes.
Other names (no longer used) for impaired glucose tolerance are borderline, subclinical, chemical, or latent diabetes.
(30 Mar 1998)
individual tolerance Tolerance to a drug that the person has never received before.
(05 Mar 2000)
oral lactose tolerance test A test for lactose deficiency; the plasma glucose response to an oral lactose load is measured as in the (oral) glucose tolerance test.
(05 Mar 2000)
test, glucose tolerance After fasting, a specific amount (100 grams) of glucose is given by mouth, and the blood levels of this sugar are measured every hour. Normally, the blood glucose should return to normal within 2 to 2 1/2 hours. The gtt is considered a classic test of carbohydrate metabolism. It is much used in the diagnosis of diabetes. The gtt depends on a number of factors including the ability of the intestine to absorb glucose, the power of the liver to take up and store glucose, the capacity of the pancreas to produce insulin, and the amount of active insulin.
(12 Dec 1998)
tolerance 1. The ability to endure unusually large doses of a drug or toxin.
2. Acquired drug tolerance, a decreasing response to repeated constant doses of a drug or the need for increasing doses to maintain a constant response.
Origin: L. Tolerantia
(18 Nov 1997)
tolerance dose The largest dose of a remedy that can be accepted without the production of injurious symptoms.
(05 Mar 2000)
exercise tolerance The exercise capacity of an individual as measured by endurance (maximal exercise duration and/or maximal attained work load) during an exercise test.
(12 Dec 1998)
frustration tolerance The level of an individual's ability to withstand frustration without developing inadequate modes of response, such as "going to pieces" emotionally.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á